International Stem Cell Corporation’s core mission is to develop therapeutic products from its own intellectual property. ISCO has pioneered a new class of human pluripotent stem cells derived from unfertilized eggs. These stem cells, known as human parthenogenetic stem cells (hpSC) retain all of the advantages required to generate targeted therapeutic tissues while being unable to generate a complete human organism.
ISCO’s Research and Development team are using these stem cells to make important breakthroughs in the treatment of a number of serious diseases where cellular replacement has been shown to be clinically beneficial, but there is no viable source of safe cells in sufficient quantities to treat patients. Such efforts are revenue intensive, however, and required ISCO to create two successful business units. Revenues from products arising from scientific discoveries made by ISCO provide practical, short-term applications of ISCO’s human cell research capabilities.
Our wholly-owned subsidiary Lifeline Cell Technology, LLC is a research products business which develops, manufactures and commercializes human cell culture products, including frozen human “primary” cells and the materials needed to grow, maintain and differentiate the cells. Lifeline Cell Technology’s products generally do not contain non-human animal material, a feature desirable with researcher working on human diseases. These research products are marketed and sold by our sales force, partners in the industry and an extensive number of distributors in Europe, Japan, China, Taiwan, Korea, India, Malaysia, Indonesia, Singapore, Middle East, New Zealand and Australia.
Our wholly-owned subsidiary Lifeline Skin Care, Inc. is a cosmeceutical business which develops, manufactures and markets cosmetic skin care products using a proprietary extract derived from our human pluripotent stem cells that has been shown to have a beneficial effect on skin cells. Lifeline Skin Care cosmetic products are sold nationally and internationally through a branded website, various retailers such as Amazon, through dermatology and cosmetic surgery offices, medical, day and resort spas and a number of international distributors.
Cyto Therapeutics Pty Limited
Our wholly-owned subsidiary Cyto Therapeutics Pty Limited is a human therapeutics business conducting our clinical trial for Parkinson’s disease in Australia. Based in Australia, Cyto Therapeutics has received regulatory approval from the Australian Therapeutic Goods Administration (TGA) and the Royal Melbourne Human Research Ethics Committee for the clinical application of ISC-hpNSC® in patients with Parkinson’s disease based on the safety and efficacy demonstrated in preclinical models. Cyto Therapeutics is currently enrolling patients for its Phase I safety study (ClinicalTrials.gov NCT02452723).